Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error

There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, which have different stated mg doses but are bioequivalent, will both …

This content is sourced from MHRA and reproduced for clinical reference. ClinicalIQ does not alter source content.